Skip to main content
. Author manuscript; available in PMC: 2014 May 15.
Published in final edited form as: J Immunol. 2013 Apr 15;190(10):5329–5336. doi: 10.4049/jimmunol.1202058

Figure 2. GRK6 inhibition increases lung metastasis and mortality.

Figure 2

For lung metastasis (A) LLC cells (3×105) were injected via the tail vein of GRK6+/+ and GRK6−/− mice (n=10). The mice were euthanized by CO2 after 4 weeks; lungs were removed and inflated with Bouin’s fixative. Photographs representative of LLC cell colonization and growth in lungs of GRK6+/+ and GRK6−/− mice. B) The number of metastatic nodules on the lungs was counted with the aid of a dissecting microscope. C) For survival rate, mice (n=14) were injected LLC cells via tail vein for lung metastasis as described above and observed daily up to sixty days for the mortality. GRK6−/− mice displayed decreased survival rate compared to GRK6+/+. The experiments were repeated twice with similar results. *** P<0.0001.